ST2 in Pulmonary Disease

In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2015-04, Vol.115 (7), p.44B-47B
Main Authors: Bajwa, Ednan K., MD, MPH, Mebazaa, Alexandre, MD, PhD, Januzzi, James L., MD
Format: Article
Language:English
Subjects:
Asthma
Biomarkers
Biomarkers - blood
Cardiovascular
Cardiovascular disease
Confidence intervals
Cytokines
Heart attacks
Humans
Inflammatory diseases
Interleukin-1 Receptor-Like 1 Protein
Ligands
Lung Diseases - blood
Mortality
Physiology
Receptors, Cell Surface - blood
Respiratory diseases
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of the ST2 pathway in clinical disease, including evidence that sST2 could be a useful biomarker in both allergic and nonallergic pulmonary disease.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2015.01.040